Status of the E2007 (perampanel) Development Program- Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications -

The Company's Official Page
http://www.eisai.co.jp/enews/enews200819.html
Back To Previous Page

Dear User,
JPubb program could not collect the texts of this press-release from the official page, which perhaps mainly comprises tables, charts or images. Please refer to the official page indicated above. -- by JPubb

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. GlaxoSmithKline and Kaken Pharmaceutical...
Kaken Pharmaceutical Co.,Ltd. 2002/12/16
2. Lundbeck and Takeda finalise plans to in...
Takeda Pharmaceutical Company Limited 2010/03/03
3. Kaken and Sunstar to sign a License Agre...
Kaken Pharmaceutical Co.,Ltd. 2007/06/19
4. Kaken to launch “GHRP Kaken 100 Injectio...
Kaken Pharmaceutical Co.,Ltd. 2005/02/23
5. Kaken Pharmaceutical and Taiyo Yakuhin E...
Kaken Pharmaceutical Co.,Ltd. 2004/04/27

Latest News: Eisai Co., Ltd.


Most Popular: Eisai Co., Ltd.

1. E7389 Demonstrated Anti-tumor Activity i...
2008/05/16
2. HUMIRA® received approval for the t...
2008/04/16

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us